← Back to Screener
Phathom Pharmaceuticals, Inc. Common Stock (PHAT)
Price$13.47
Favorite Metrics
Price vs S&P 500 (26W)2.84%
Price vs S&P 500 (4W)8.17%
Market Capitalization$1.04B
All Metrics
Book Value / Share (Quarterly)$0.31
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.34
Price vs S&P 500 (YTD)-24.63%
Gross Margin (TTM)87.09%
Net Profit Margin (TTM)-126.35%
EPS (TTM)$-3.05
10-Day Avg Trading Volume0.97M
EPS Excl Extra (TTM)$-3.05
EPS (Annual)$-3.03
ROI (Annual)-88.87%
Gross Margin (Annual)87.09%
Cash / Share (Quarterly)$1.82
Revenue Growth QoQ (YoY)94.12%
ROA (Last FY)-85.37%
Revenue Growth TTM (YoY)216.93%
EBITD / Share (TTM)$-2.19
Operating Margin (TTM)-91.36%
Cash Flow / Share (Annual)$-2.34
P/B Ratio59.05x
P/B Ratio (Quarterly)44.50x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)8.54x
Net Interest Coverage (TTM)-2.62x
ROA (TTM)-84.78%
EPS Incl Extra (Annual)$-3.03
Current Ratio (Annual)1.73x
Quick Ratio (Quarterly)1.58x
3-Month Avg Trading Volume1.10M
52-Week Price Return212.19%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-0.31
P/S Ratio (Annual)5.94x
Asset Turnover (Annual)0.68x
52-Week High$18.31
EPS Excl Extra (Annual)$-3.03
CapEx CAGR (5Y)-26.11%
26-Week Price Return11.59%
Quick Ratio (Annual)1.58x
13-Week Price Return-12.88%
Total Debt / Equity (Annual)1.24x
Current Ratio (Quarterly)1.73x
Enterprise Value$1,495.841
Asset Turnover (TTM)0.67x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-126.35%
Cash / Share (Annual)$1.82
3-Month Return Std Dev60.83%
Net Income / Employee (TTM)$-1
ROE (Last FY)-199.28%
Net Interest Coverage (Annual)-2.62x
EPS Basic Excl Extra (Annual)$-3.03
Receivables Turnover (TTM)3.00x
Total Debt / Equity (Quarterly)12.38x
EPS Incl Extra (TTM)$-3.05
ROI (TTM)-17.40%
P/S Ratio (TTM)5.94x
Revenue / Share (Annual)$2.40
Tangible BV / Share (Annual)$-1.80
Forward P/E89.30x
Price vs S&P 500 (52W)177.09%
Year-to-Date Return-20.49%
5-Day Price Return4.10%
EPS Normalized (Annual)$-3.03
ROA (5Y Avg)-83.68%
Net Profit Margin (Annual)-126.35%
Month-to-Date Return18.72%
Cash Flow / Share (TTM)$-3.74
EBITD / Share (Annual)$-2.19
Operating Margin (Annual)-91.36%
LT Debt / Equity (Annual)1.24x
LT Debt / Equity (Quarterly)12.36x
EPS Basic Excl Extra (TTM)$-3.05
P/B Ratio (Annual)8.32x
Inventory Turnover (TTM)5.18x
Pretax Margin (TTM)-126.35%
Book Value / Share (Annual)$2.36
Price vs S&P 500 (13W)-15.74%
Beta0.66x
Revenue / Share (TTM)$2.37
ROE (TTM)-232.78%
52-Week Low$2.21
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.25
4.18
4.18
4.24
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
PHATPhathom Pharmaceuticals, Inc. Common Stock | 5.94x | 216.93% | 87.09% | — | $13.47 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Phathom Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for gastrointestinal diseases. Its lead product, vonoprazan, is an oral potassium competitive acid blocker with demonstrated efficacy in treating gastroesophageal reflux disease and Helicobacter pylori infection. The compound exhibits rapid, potent, and durable acid-suppressive effects.